- Home
- CNOBP vs CANF Comparison
CNOBP vs CANF Comparison
Compare CNOBP & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNOBP
- CANF
- Stock Information
- Founded
- CNOBP N/A
- CANF 1994
- Country
- CNOBP United States
- CANF Israel
- Employees
- CNOBP 493
- CANF N/A
- Industry
- CNOBP Major Banks
- CANF Biotechnology: Pharmaceutical Preparations
- Sector
- CNOBP Finance
- CANF Health Care
- Exchange
- CNOBP Nasdaq
- CANF Nasdaq
- Market Cap
- CNOBP N/A
- CANF 7.9M
- IPO Year
- CNOBP N/A
- CANF N/A
- Fundamental
- Price
- CNOBP $22.00
- CANF $1.09
- Analyst Decision
- CNOBP
- CANF Strong Buy
- Analyst Count
- CNOBP 0
- CANF 2
- Target Price
- CNOBP N/A
- CANF $14.00
- AVG Volume (30 Days)
- CNOBP N/A
- CANF 422.0K
- Earning Date
- CNOBP N/A
- CANF 05-13-2025
- Dividend Yield
- CNOBP N/A
- CANF N/A
- EPS Growth
- CNOBP N/A
- CANF N/A
- EPS
- CNOBP N/A
- CANF N/A
- Revenue
- CNOBP N/A
- CANF $674,000.00
- Revenue This Year
- CNOBP N/A
- CANF $461.72
- Revenue Next Year
- CNOBP N/A
- CANF N/A
- P/E Ratio
- CNOBP N/A
- CANF N/A
- Revenue Growth
- CNOBP N/A
- CANF N/A
- 52 Week Low
- CNOBP N/A
- CANF $1.22
- 52 Week High
- CNOBP N/A
- CANF $4.69
- Technical
- Relative Strength Index (RSI)
- CNOBP 47.68
- CANF 34.28
- Support Level
- CNOBP $21.91
- CANF $1.13
- Resistance Level
- CNOBP $22.82
- CANF $1.19
- Average True Range (ATR)
- CNOBP 0.22
- CANF 0.11
- MACD
- CNOBP 0.08
- CANF -0.02
- Stochastic Oscillator
- CNOBP 100.00
- CANF 1.35
About CNOBP ConnectOne Bancorp Inc. Depositary Shares each representing a 1/40th interest in a share of 5.25% Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock Series A
ConnectOne Bancorp Inc is a community-based, full-service New Jersey-chartered commercial bank. Substantially all loans are secured with various types of collateral, including business assets, consumer assets and commercial/residential real estate. Each borrower's ability to repay its loans is dependent on the conversion of assets, cash flows generated from the borrowers' business, real estate rental and consumer wages.
About CANF Can-Fite Biopharma Ltd Sponsored ADR (Israel)
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).